– UK, Brentford – GlaxoSmithKline PLC (LSE:GSK), today announces that Dr Laurie Glimcher has been appointed to the Board of the Company as a Non-Executive Director and has been deemed a Scientific and Medical Expert. Dr Glimcher will join the Board on 1 September 2017.
Philip Hampton, Chairman of GlaxoSmithKline plc, said: “I am delighted Laurie is joining the Board. Laurie brings a wealth of expertise in scientific and medical innovation and public health which will be invaluable to GSK. “
Dr Glimcher is currently Professor of Medicine at Harvard Medical School and is CEO, President and an Attending Physician at the Dana-Farber Cancer Institute.
In addition to a number of senior leadership positions held at both Harvard Medical School and Harvard School of Public Health, Dr Glimcher has also served as Stephen and Suzanne Weiss Dean and Professor of Medicine at Weill Cornell Medical College and as an Attending Physician at the New York Presbyterian Hospital/Weill Cornell Medical Center.
Dr Glimcher is a member of the Blue Ribbon Panel Advisory Board of the National Cancer Institute and of the American Asthma Foundation. She is a Non-Executive Director of the Parker Institute for Cancer Immunotherapy and of the Waters Corporation, where she also serves on their Corporate Governance Committee. Dr Glimcher recently decided to step down from the Board of Bristol-Myers Squibb Co (BMS) after serving for 20 years on its Board.
Dr Glimcher has recently been awarded the Kober Medal from the American Association of Physicians for a lifetime of achievements in the field of internal medicine. She has also received the L’Oreal Laureate Award for her discoveries in immunology, and the Marion Fay Spencer award for her scholarship and commitment to the application of sciences to healthcare. She is also a member of the Lasker Award Jury, a Fellow of the American Academy of Arts and Sciences, a Member of the National Academy of Medicine, a Member of the National Academy of Sciences and a Fellow of the Royal Society of Biology.
On joining the Board Dr Glimcher will become a member of the Board’s Science and Audit & Risk Committees.
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D ‘Risk factors’ in the company’s Annual Report on Form 20-F for 2016.
For more information : http://www.gsk.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
